We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcerative colitis.
我们进行了一项双盲，多中心研究，比较了美沙美拉明与美沙酮对安慰剂治疗活动性溃疡性结肠炎的疗效。
The median time to relapse after stopping treatment was about 38 days in both the patients who switched to placebo and in the active treatment group.
包括改服安慰剂和主动治疗组的所有患者在内，在停止治疗后中位复发时间为38天。
At 52 weeks, all of the active treatment groups showed significant reduction in LDL cholesterol from baseline and compared to placebo. The treatment was also well tolerated.
在治疗的第52周，所有使用阿托伐他汀治疗的患者，其低密度脂蛋白水平不管是基线水平还是与安慰剂比较都显著降低。
Results: a total of 88 women, 47 receiving active treatment and 41 in the placebo group, completed the study.
结果：共88例妇女(试验组47例、安慰剂对照组41例)完成了试验。
Of course, we don't know whether this drug combination is equally effective as another active treatment because this was a placebo control trial.
当然，由于这是安慰剂对照的试验，我们不知道这种药物组合是否和其他治疗等效。
STELARA patients received a third dose at week 16, while placebo-treated patients crossed over to receive active treatment at weeks 12 and 16.
STELARA患者接受16周三分之一剂量，而安慰剂治疗的患者越过收到12至16周时积极治疗。
STELARA patients received a third dose at week 16, while placebo-treated patients crossed over to receive active treatment at weeks 12 and 16.
STELARA患者接受16周三分之一剂量，而安慰剂治疗的患者越过收到12至16周时积极治疗。
应用推荐